Johnson & Johnson (XSWX:JNJ) Accounts Payable: CHF8,235 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:JNJ Johnson & Johnson XSWX:JNJ
76 GF Score
Price CHF205.10
GF Value CHF154.50
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Accounts Payable?

Johnson & Johnson XSWX:JNJ -1.82% 76 Accounts Payable is CHF8,235 Mil as of Mar. 2026. GuruFocus rates XSWX:JNJ with a GF Score™ of 76/100 and a GF Value™ of CHF154.50 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Johnson & Johnson's Accounts Payable for the quarter that ended in Mar. 2026 was CHF8,235 Mil.

Johnson & Johnson's quarterly Accounts Payable increased from Sep. 2025 (CHF7,662 Mil) to Dec. 2025 (CHF9,556 Mil) but then declined from Dec. 2025 (CHF9,556 Mil) to Mar. 2026 (CHF8,235 Mil).

Johnson & Johnson's annual Accounts Payable increased from Dec. 2023 (CHF8,330 Mil) to Dec. 2024 (CHF9,193 Mil) and increased from Dec. 2024 (CHF9,193 Mil) to Dec. 2025 (CHF9,556 Mil).

Johnson & Johnson Accounts Payable Related Terms

Johnson & Johnson Accounts Payable Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Accounts Payable Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,181.66 9,212.59 8,329.75 9,193.29 9,555.63

Johnson & Johnson Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,696.13 7,662.46 9,555.63 8,235.16 0.00
XSWX:JNJ
76GF Score
Johnson & Johnson XSWX:JNJ
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson & Johnson Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF8,235 Mil mean?
Johnson & Johnson (XSWX:JNJ) has a Accounts Payable of CHF8,235 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Johnson & Johnson and its competitors.
Is Johnson & Johnson's Accounts Payable too high?
Johnson & Johnson's current Accounts Payable is CHF8,235 Mil. Overall, Johnson & Johnson has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Accounts Payable compare to ABBV and MRK?
Johnson & Johnson's Accounts Payable of CHF8,235 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Johnson & Johnson and its competitors. Johnson & Johnson's current Accounts Payable is CHF8,235 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (XSWX:JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF154.50, compared to a current price of CHF205.10 — trading 32.8% above its estimated fair value. The current Accounts Payable is CHF8,235 Mil. Johnson & Johnson's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Johnson & Johnson (XSWX:JNJ), the current Accounts Payable is CHF8,235 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (XSWX:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of CHF205.10 is trading 32.8% above its estimated GF Value™ of CHF154.50. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for XSWX:JNJ:

  • Accounts Payable: CHF8,235 Mil
  • GF Value™: CHF154.50 vs. price of CHF205.10 (32.8% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
76GF Score

Get the complete analysis for XSWX:JNJ

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF205.10
Price
CHF154.50
GF Value